# Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

> **NCT03870919** · NA · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 200 (actual)

## Conditions studied

- Breast Cancer Stage IV
- Radiotherapy
- Surgery

## Interventions

- **DRUG:** Palbociclib
- **OTHER:** locoregional treatment

## Key facts

- **NCT ID:** NCT03870919
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-23
- **Primary completion:** 2024-08-18
- **Final completion:** 2027-10-23
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03870919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03870919, "Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03870919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*